Fax: (+011) 39-06-20903221
Report of 82 patients enrolled in an Italian compassionate program
Article first published online: 14 JUL 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 4, pages 1014–1022, 15 February 2012
How to Cite
Maurillo, L., Venditti, A., Spagnoli, A., Gaidano, G., Ferrero, D., Oliva, E., Lunghi, M., D'Arco, A. M., Levis, A., Pastore, D., Di Renzo, N., Santagostino, A., Pavone, V., Buccisano, F. and Musto, P. (2012), Azacitidine for the treatment of patients with acute myeloid leukemia . Cancer, 118: 1014–1022. doi: 10.1002/cncr.26354
The first two authors and the last author contributed equally to this article.
The following authors took part into the “Italian Compassionate Program”: Maria Teresa Voso, Chair of Hematology, “Sacro Cuore” Catholic University, Rome; Maria Antonietta Aloe Spiriti, “S. Andrea” Hospital, Rome; Giuseppe Palumbo, Chair of Hematology, University of Catania, Catania; Grazia Sanpaolo, Department of Hematology, Scientific Institute of Research and Cure, “Casa Sollievo della Sofferenza” Hospital, S. Giovanni Rotondo, Foggia; Giuseppe Mele, Department of Hematology, “A. Perrino” Hospital, Brindisi; Lucia Ciuffreda, Department of Hematology, “S. Nicola Pellegrino” Hospital, Trani; Fortunato Morabito, Department of Hematology, “Annunziata” Hospital, Cosenza; Giorgina Specchia, Chair of Hematology, University of Bari, Bari; Felicetto Ferrara, Department of Hematology, “A. Cardarelli” Hospital, Naples; Valeria Santini, Department of Hematology, University of Florence, Florence.
- Issue published online: 3 FEB 2012
- Article first published online: 14 JUL 2011
- Manuscript Accepted: 20 MAY 2011
- Manuscript Revised: 27 APR 2011
- Manuscript Received: 22 FEB 2011
- 2On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274., , , et al.
- 17Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 [abstract]. Ann Hematol. 1994; 68( suppl): A12. Abstract 46., , , et al.
- 27Independent prognostic factors for AML outcome [serial online]. Am Soc Hematol Educ Program. 2009; 385-395., .
- 31The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 227., , , et al.
- 32Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 1054., , , et al.
- 33Azacytidine (AZA) as first line therapy in AML: results of the French ATU Program [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 843., , , et al.
- 41Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007; 109: 5129-5135., , , et al.
- 42A comparison of low dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 1114-1124., , , et al.
- 46Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (Pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008: 112. Abstract 3636., , , et al.